The World Health Organization (WHO) has advised against using Gilead’s remdesivir in patients hospitalized with coronavirus, weeks after the drug was shown to have “little or no effect” during the agency’s multicountry Solidarity Trial. “The … panel found a lack of evidence that remdesivir improved outcomes that matter to patients,” the GDP said Friday, according to Reuters. PFIZER TO FILE CORONAVIRUS VACCINE FOR EMERGENCY USE AUTHORIZATION: HERE'S WHAT IT MEANSHowever, the WHO’s Solidarity Trial showed the drug had little or no effect on 28-day mortality or length of hospital stay for coronavirus patients. CLICK HERE FOR COMPLETE CORONAVIRUS COVERAGE“Veklury is recognized as a standard of care for the treatment of hospitalized patients with COVID-19 in guidelines from numerous credible national organizations,” the company said, according to Reuters. The guidelines were issued a day after the FDA granted emergency approval to a drug combo that included remdesivir to treat hospitalized coronavirus patients.

Source: Fox News November 20, 2020 15:11 UTC